Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population - Results from the HUNT 2 study

British Journal of Haematology

Volumn 141, Issue 4, 2008, Pages 529-535

  Næss, Inger Anne ^a,b   Christiansen, Sverre C ^c   Romundstad, Pål R ^a   Cannegieter, Suzanne C ^c   Blom, Henk J ^d   Rosendaal, Frits R ^c   Hammerstrøm, Jens ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Deep vein thrombosis; Homocysteine; MTHFR 677TT genotype; Pulmonary embolism; Venous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 42249111541     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07073.x     Document Type: Article

References (27)

1. Bezemer, I.D., Doggen, C.J., Vos, H.L. Rosendaal, F.R. (2007) No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Archives of Internal Medicine, 167, 497 501.
2. Bonaa, K.H., Njolstad, I., Ueland, P.M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J.E., Arnesen, E. Rasmussen, K. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine, 354, 1578 1588.
3. de Bree, A., Verschuren, W.M., Blom, H.J., de Graaf-Hess, A., Trijbels, F.J. Kromhout, D. (2001) The homocysteine distribution: (mis)judging the burden. Journal of Clinical Epidemiology, 54, 462 469.
4. Callaham, M.L., Wears, R.L., Weber, E.J., Barton, C. Young, G. (1998) Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. JAMA, 280, 254 257.
5. Fiskerstrand, T., Refsum, H., Kvalheim, G. Ueland, P.M. (1993) Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clinical Chemistry, 39, 263 271.
6. Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Matthews, R.G., Boers, G.J., den Heijer, M., Kluijtmans, L.A., van den Heuvel, L.P. Rozen, R. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics, 10, 111 113.
7. den Heijer, M. (2003) Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clinical Chemistry and Laboratory Medicine, 41, 1404 1407.
8. den Heijer, M., Blom, H.J., Gerrits, W.B., Rosendaal, F.R., Haak, H.L., Wijermans, P.W. Bos, G.M. (1995) Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet, 345, 882 885.
9. den Heijer, M., Koster, T., Blom, H.J., Bos, G.M., Briet, E., Reitsma, P.H., Vandenbroucke, J.P. Rosendaal, F.R. (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. New England Journal of Medicine, 334, 759 762.
10. den Heijer, M., Lewington, S. Clarke, R. (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Journal of Thrombosis and Haemostasis, 3, 292 299.
11. den Heijer, M., Willems, H.P., Blom, H.J., Gerrits, W.B., Cattaneo, M., Eichinger, S., Rosendaal, F.R. Bos, G.M. (2007) Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood, 109, 139 144.
12. Holmen, J., Midthjell, K. Krüger, Ø. Langhammer, A. (2003) The Nord-Trøndelag Health Study 1995-1997 (HUNT2). Norsk Epidemiologi, 13, 19 32.
13. Kluijtmans, L.A., Kastelein, J.J., Lindemans, J., Boers, G.H., Heil, S.G., Bruschke, A.V., Jukema, J.W., van den Heuvel, L.P., Trijbels, F.J., Boerma, G.J., Verheugt, F.W., Willems, F. Blom, H.J. (1997) Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation, 96, 2573 2577.
14. Lonn, E., Yusuf, S., Arnold, M.J., Sheridan, P., Pogue, J., Micks, M., McQueen, M.J., Probstfield, J., Fodor, G., Held, C. Genest, Jr., J. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine, 354, 1567 1577.
15. Naess, I.A., Christiansen, S.C., Romundstad, P., Cannegieter, S.C., Rosendaal, F.R. Hammerstrom, J. (2007) Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis, 5, 692 699.
16. Nygard, O., Vollset, S.E., Refsum, H., Stensvold, I., Tverdal, A., Nordrehaug, J.E., Ueland, M. Kvale, G. (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA, 274, 1526 1533.
17. Ray, J.G., Shmorgun, D. Chan, W.S. (2002) Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiology of Haemostasis and Thrombosis, 32, 51 58.
18. Ray, J.G., Kearon, C., Yi, Q., Sheridan, P. Lonn, E. (2007) Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Annals of Internal Medicine, 146, 761 767.
19. Ridker, P.M., Hennekens, C.H., Selhub, J., Miletich, J.P., Malinow, M.R. Stampfer, M.J. (1997) Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation, 95, 1777 1782.
20. Rosendaal, F.R. (1999) Risk factors for venous thrombotic disease. Thrombosis and Haemostasis, 82, 610 619.
21. Rothman, K.J. (2002) Epidemiology: An Introduction. Oxford University Press, New York.
22. The Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA, 288, 2015 2022.
23. Toole, J.F., Malinow, M.R., Chambless, L.E., Spence, J.D., Pettigrew, L.C., Howard, V.J., Sides, E.G., Wang, C.H. Stampfer, M. (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, 291, 565 575.
24. Tsai, A.W., Cushman, M., Tsai, M.Y., Heckbert, S.R., Rosamond, W.D., Aleksic, N., Yanez, N.D., Psaty, B.M. Folsom, A.R. (2003) Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). American Journal of Hematology, 72, 192 200.
25. Wald, D.S., Law, M. Morris, J.K. (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ, 325, 1202 1208.
26. Wald, D.S., Wald, N.J., Morris, J.K. Law, M. (2006) Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ, 333, 1114 1117.
27. Willems, H.P., Bos, G.M., Gerrits, W.B., den, H.M., Vloet, S. Blom, H.J. (1998) Acidic citrate stabilizes blood samples for assay of total homocysteine. Clinical Chemistry, 44, 342 345.